Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Theravance Biopharma, Inc. (TBPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update",
"MEDICINES THAT MAKE A DIFFERENCE"
06/09/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
05/08/2023 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update",
"Slide deck entitled First Quarter 2023 Financial Results and Business Update"
05/03/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Continued Transformation Positions Theravance Biopharma for Value Creation"
02/27/2023 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update",
"Slide deck entitled Strategic Actions and Fourth Quarter / Full Year 2022 Financial Results and Business Update"
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets",
"Slide deck entitled Theravance Biopharma Investor Presentation"
12/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/07/2022 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer",
"MEDICINES THAT MAKE A DIFFERENCE"
11/02/2022 8-K Quarterly results
09/20/2022 8-K Other Events  Interactive Data
09/19/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Slide deck entitled Transformed and Focused on Medicines that Make a Difference®"
08/25/2022 8-K Other Events  Interactive Data
08/04/2022 8-K Quarterly results
07/20/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/28/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension",
"Slide deck entitled Study 0170 (REDWOOD) Ampreloxetine Phase 3 Results"
02/23/2022 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"Slide deck entitled Fourth Quarter and Full Year 2021 Financial Results and Business Update"
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Slide deck entitled JP Morgan Healthcare Conference",
"Slide deck entitled Appendix Slides to Investor Presentation"
12/22/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
12/16/2021 8-K Other Events  Interactive Data
11/16/2021 8-K Other Events  Interactive Data
11/03/2021 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update",
"Slide deck entitled Third Quarter 2021 Financial Results and Business Update"
09/15/2021 8-K Quarterly results
08/23/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update",
"MEDICINES THAT MAKE A DIFFERENCE",
"MEDICINES THAT MAKE A DIFFERENCE"
06/25/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement among Theravance Biopharma, SVB Leerink LLC, Evercore Group L.L.C. and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters",
"Opinion of Maples and Calder",
"Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares DUBLIN, IRELAND —June 24, 2021 — Theravance Biopharma, Inc. , a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today that it intends to offer its ordinary shares in an underwritten public offering. Theravance Biopharma also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Theravance Biopharma intends to use the net proceeds from this offer...",
"Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares"
06/21/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy